{
  "docId": "019dd923-622b-71dc-a6da-7792191b0575",
  "docSlug": "ca94acfa263b",
  "documentTitle": "Pfizer Inc. (PFE)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 68,
  "pageCount": 74,
  "prevPage": 67,
  "nextPage": 69,
  "slideType": "valuation_reveal",
  "function": "show_valuation_bridge",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a waterfall chart to frame a critique of management's capital allocation efficiency.",
  "elementsJson": [
    "headline_text",
    "waterfall_chart",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6da-7792191b0575/68",
  "deckHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6da-7792191b0575#slide-68",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.48
      },
      "kind": "callout",
      "text": "We need management focused on achieving at least 38% revenue growth return and the Board focused on accountability and raising expectations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ceb12ca2-5065-444c-a4e7-a8b623834fed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Pfizer Sales Bridge (Ex. COVID): 2023 to 2030",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07f53ffb-82c4-4ef9-b746-412aa5c322a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Revenue Return: 15%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-2b66-7100-896c-71f8bb2ee168",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.04,
        "y": 0.975
      },
      "kind": "source-note",
      "text": "Source: Public company filings, Wall Street Research, Visible Alpha, and Starboard estimates.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "667a80cf-bb05-48bc-af90-fe146d7908cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.68,
        "y": 0.3
      },
      "kind": "table",
      "text": "Gross Revenue Growth $19 billion; R&D and M&A $128 billion; Revenue Return 15%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de3dc6b1-dd6c-459d-91f7-fe7a8b745a26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "title",
      "text": "This is not acceptable.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a069091-495a-4463-8cea-67b3a3de8d2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Adjusting For LOEs, Pfizer Is Currently Expected to Grow by $19 Billion of Revenue From 2023 to 2030",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ec7c6ac-918a-464d-a420-a0aa594c6a84",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "waterfall-bridge",
      "slug": null,
      "matchId": "600d4f68-2c97-446b-aa77-013abc5a17af",
      "evidence": "The chart visually decomposes the change in revenue from 2023 to 2030.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 74,
      "from": 61,
      "beatId": "2f655379-f0eb-4ab4-834d-dbd332abba28",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document urges the board to take action to improve Pfizer's performance, including holding management accountable for improving returns on capital.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 73,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "54ce6058-bed8-43c5-8780-84fb43f33c5e",
      "evidence": "The document highlights the significant losses in value that Pfizer has experienced due to its poor performance, and urges the board to take action to improve this.",
      "position": 0,
      "objective": "What are the consequences of not improving Pfizer's performance?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 73,
      "from": 3,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "f6f940a6-6451-4a43-940f-82e2afbdbeb8",
      "evidence": "The document presents several potential solutions to improve Pfizer's performance, including improving its return on R&D investments and holding management accountable for improving performance.",
      "position": 1,
      "objective": "Can Pfizer achieve higher returns on capital?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}